Does Trulicity Lower A1C?
Yes, Trulicity (dulaglutide) lowers A1C in adults with type 2 diabetes. Clinical trials showed reductions of 0.7% to 1.6% from baseline A1C levels (typically 7.5-8.5%) over 26-52 weeks, depending on dose and combination therapy.[1][2]
How Much A1C Reduction Can Patients Expect?
In monotherapy trials, 1.5 mg weekly doses reduced A1C by about 0.8-1.0% at 26 weeks. Added to metformin or other agents like SGLT2 inhibitors, reductions reached 1.4-1.6%. Results vary by baseline A1C, duration of diabetes, and adherence; higher baselines (>9%) see larger drops.[1][3]
How Does Trulicity Work to Lower A1C?
Trulicity is a GLP-1 receptor agonist that mimics incretin hormones. It boosts insulin secretion after meals, slows gastric emptying, and reduces glucagon, lowering postprandial glucose. Weekly subcutaneous injections target chronic hyperglycemia, reflected in A1C over 2-3 months.[1][2]
Compared to Other GLP-1 Agonists Like Ozempic or Victoza
Trulicity matches or exceeds A1C reductions from semaglutide (Ozempic: 1.0-1.5%) and liraglutide (Victoza: 0.8-1.2%) in head-to-head trials, with similar cardiovascular benefits but easier weekly dosing vs. daily. Ozempic may edge out on weight loss.[3][4]
When Do A1C Changes Show Up?
Noticeable drops occur within 4-12 weeks, with full effects by 26 weeks. Monitor every 3 months; if no >0.5% reduction after 6 months, doctors often adjust dose or switch.[1]
What If It Doesn't Lower A1C Enough?
Non-response (A1C <0.5% drop) affects 20-30% of patients, often due to poor adherence, high baseline carbs, or insulin resistance. Alternatives include adding basal insulin or switching to tirzepatide (Mounjaro), which cuts A1C 1.8-2.4%.[3][5]
Common Side Effects Tied to A1C Control
Nausea (15-20%), vomiting, and diarrhea peak early but fade; they don't directly impact A1C but can affect adherence. Hypoglycemia risk is low (4-6%) unless combined with insulin/sulfonylureas.[1][2]
[1]: Trulicity Prescribing Information (Eli Lilly)
[2]: FDA Approval Label for Dulaglutide
[3]: AWARD-6 Trial: Dulaglutide vs Liraglutide (NEJM)
[4]: SURPASS-2 Trial: Tirzepatide vs Semaglutide
[5]: ADA Standards of Care 2023